Search research articles
Contact Us
Filters
Showing results (11-20 of 26) with videos related to
Page
of 3
Sort By:
Clinical Colorectal Cancer
|
March 29, 2021
Patient Risk Subgroups Predict Benefit of Adjuvant Chemotherapy in Stage II Rectal Cancer Patients Following Neoadjuvant Chemoradiation and Total Mesorectal Excision
Samer Naffouje, Arvind Sabesan, Benjamin D Powers, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 28, 2003
Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer
Mark A Socinski, Marcus A Neubauer, Jairo Olivares, et al.
American Journal of Clinical Oncology
|
June 1, 2005
Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone
Celeste Lindley, Susan Goodin, Jeannine McCune, et al.
Nature Communications
|
August 27, 2016
The tumour suppressor CYLD regulates the p53 DNA damage response
Vanesa Fernández-Majada, Patrick-Simon Welz, Maria A Ermolaeva, et al.
Cancer Immunology Research
|
February 14, 2016
Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
Jeffrey Weber, Geoffrey Gibney, Ragini Kudchadkar, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 7, 2002
Benefits of external beam irradiation for peripheral arterial bypass: preliminary report on a phase I study
Arvind B Soni, Karl A Illig, Yaron Sternbach, et al.
The Oncologist
|
October 4, 2016
A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
Alberto A Chiappori, Gregory A Otterson, Afshin Dowlati, et al.
Nature Communications
|
April 28, 2016
Exosomal microRNA miR-92a concentration in serum reflects human brown fat activity
Yong Chen, Joschka J Buyel, Mark J W Hanssen, et al.
Cell Reports
|
March 19, 2013
Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA
Kerstin Brinkmann, Paola Zigrino, Axel Witt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 16, 2019
BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells
Cigdem Atay, Taekyoung Kwak, Sergio Lavilla-Alonso, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 26) with videos related to
Sort By:
Page
of 3
Clinical Colorectal Cancer
|
March 29, 2021
Patient Risk Subgroups Predict Benefit of Adjuvant Chemotherapy in Stage II Rectal Cancer Patients Following Neoadjuvant Chemoradiation and Total Mesorectal Excision
Samer Naffouje, Arvind Sabesan, Benjamin D Powers, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 28, 2003
Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer
Mark A Socinski, Marcus A Neubauer, Jairo Olivares, et al.
American Journal of Clinical Oncology
|
June 1, 2005
Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone
Celeste Lindley, Susan Goodin, Jeannine McCune, et al.
Nature Communications
|
August 27, 2016
The tumour suppressor CYLD regulates the p53 DNA damage response
Vanesa Fernández-Majada, Patrick-Simon Welz, Maria A Ermolaeva, et al.
Cancer Immunology Research
|
February 14, 2016
Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
Jeffrey Weber, Geoffrey Gibney, Ragini Kudchadkar, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 7, 2002
Benefits of external beam irradiation for peripheral arterial bypass: preliminary report on a phase I study
Arvind B Soni, Karl A Illig, Yaron Sternbach, et al.
The Oncologist
|
October 4, 2016
A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
Alberto A Chiappori, Gregory A Otterson, Afshin Dowlati, et al.
Nature Communications
|
April 28, 2016
Exosomal microRNA miR-92a concentration in serum reflects human brown fat activity
Yong Chen, Joschka J Buyel, Mark J W Hanssen, et al.
Cell Reports
|
March 19, 2013
Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA
Kerstin Brinkmann, Paola Zigrino, Axel Witt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 16, 2019
BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells
Cigdem Atay, Taekyoung Kwak, Sergio Lavilla-Alonso, et al.
Page
of 3